Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.
| 1.28 | |
| 1.18 | |
| - | |
| 1.45 | |
| 1.18 | |
| 0.52-7.79 | |
| 42 847 K | |
| 34 649 K | |
| 0 | |
| -0.53 | |
| 1.547 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this piece, we will take a look at the 13 hot stocks to invest in according to Wall Street analysts. If you want to skip our overview of the stock market and the latest news, then you can skip ahea...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
